Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChan, Matthew M K-
dc.contributor.otherDavidson, A.-
dc.contributor.otherVeillard, A.S.-
dc.contributor.otherHughes, B.G.-
dc.contributor.otherBoyer, M.-
dc.contributor.otherBriscoe, K.-
dc.contributor.otherBegbie, S.-
dc.contributor.otherAbdi, E.-
dc.contributor.otherCrombie, C.-
dc.contributor.otherLong, J.-
dc.contributor.otherBoyce, A.-
dc.contributor.otherLewis, C.R.-
dc.contributor.otherVarma, S.-
dc.contributor.otherBroad, A.-
dc.contributor.otherMuljadi, N.-
dc.contributor.otherChinchen, S.-
dc.contributor.otherEspinoza, D.-
dc.contributor.otherCoskinas, X.-
dc.contributor.otherPavlakis, N.-
dc.contributor.otherMillward, M.-
dc.contributor.otherStockler, M.R.-
dc.identifier.citationVolume 26, Issue 11, pp. 2280-2286en
dc.description.abstractBACKGROUND: We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. PATIENTS AND METHODS: Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. RESULTS: Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. CONCLUSION: The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further. CLINICAL TRIALS NUMBER: Australian New Zealand Clinical Trials Registry Number ACTRN12608000588392.en
dc.titleA phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialen
dc.typeJournal Articleen
dc.identifier.journaltitleAnnals of Oncologyen
dc.type.studyortrialRandomized Controlled Clinical Trial/Controlled Clinical Trialen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Oncology / Cancer
Show simple item record

Page view(s)

checked on Mar 28, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.